m625 is not a clinical decision tool · not a publisher · not an expert authority · not a simulator. It is a cross-domain Roll-formalized evidence atlas with public audit + attack surface.
Why a regulator (or regulator-adjacent reviewer) would come to evidence.x1000.ai
A FDA / EMA / NMPA-adjacent reviewer evaluating new modalities (in-vivo CD19 platforms, n=1 rare-disease n-of-1, RNA gene-writing) reads about Roll-formalized evidence patterns and asks: how does this map to existing review frameworks? Pain points (see 05_docs/M625_PERSONAS.md):
new modalities outpace regulatory framework cycles;
cross-period follow-up requirements (5-yr vs 15-yr) are hard to set at first-in-human;
patient registry data formats vary by sponsor;
NCNU-style hard constraints (no individual prediction, no clinical decision directive, no cure / reverse lexicon) are hard to formalize across sponsors.
m625 does not advise on any specific submission. **m625 shows that millennium audit V1.1's 4-layer structure has a structural analog with FDA's 4-layer review process (informational, not prescriptive)**, and that NCNU-5 + W7-N can serve as a sponsor self-audit pattern.
This is not regulatory advice. This is not a regulatory submission template. (See "What this demo will not say".)
The Roll-formalized object (anchored on m604 千年审计 V1.1)
Field
Value
Upstream standard
m604 千年审计 V1.1 (m604 sovereign · /data/projects/m604_RollDeep/01_standards/ and 04_audit_reports/)
per 09_walls/forbidden_vocabulary.yml · m604 NCNU lexicon authoritative
How a regulator reviewer should read this evidence (≤ 5 minutes)
Structural analog to FDA 4-layer process — informational only.
- Layer 1 (Roll Kernel Consistency) ↔ regulator-side "primary endpoint and trial design integrity"
- Layer 2 (Vocabulary Freeze) ↔ regulator-side "labeling and claim language review"
- Layer 3 (Evidence Protocol) ↔ regulator-side "evidence quality + corroboration"
- Layer 4 (Structural Integrity) ↔ regulator-side "cross-program consistency review"
The analogy is *structural*, not *operational*. A regulator does NOT outsource review to a Roll engine. (NCNU P_1)
NCNU-5 as sponsor self-audit pattern. A sponsor that submits a deck containing any of the 5 NCNU patterns (clinical decision / individual fate / individual prediction / moral attribution / cross-period reverse) has by definition not self-audited. This is a signal, not a rule.
Cross-period K4.1 declaration. For rare-disease n=1 / n-of-few studies where long-term follow-up is required, the K4.1 3-bit declaration (X visibly altered? Φ visibly altered? Δ-B visibly altered?) is a structural way to specify what "cross-period closure" means — independent of any specific endpoint definition.
Public BLOCKED log model. A regulator could read the m610 ATTACK_SURFACE_v0.1 honest-disclosure pattern as a sponsor self-disclosure protocol: every attack-surface entry catalogues a way the sponsor's evidence could be wrong. A sponsor that maintains such a log is structurally more trustworthy than one that does not — independent of whether the underlying evidence is approvable.
The 4-layer audit structure is m604-sovereign and was designed for cross-domain Roll evidence (cancer / neuro / longevity / autism / neurodegen / CKD / rare). Cross-mapping to FDA / EMA / NMPA review processes is structural-analog only. transferability_pct: not quantified; the analogy is offered as informational reference, not as a substitutable framework.
What this demo will not say (anti-drift)
❌ It does not assert any specific FDA / EMA / NMPA review pathway is "wrong" or "right".
❌ It does not recommend a sponsor adopt Roll Principle as a regulatory standard.
❌ It does not name, rank, or evaluate any specific submission.
❌ It does not promise restoration or assert clinical efficacy (NCNU P_1 + cure lexicon, audit gate G2.2).
❌ It does not affirm or vouch for any reviewer, agency, or sponsor (m517 W7-N inheritance, audit gate G2.3).
Falsifying prediction (per W6.5 + Roll EPP-3)
The structural-analog claim would be falsified by either of:
a regulator-side review of the m604 千年审计 V1.1 4-layer structure that concludes the layers do not map structurally to standard regulatory review primitives (i.e., the analogy is misleading); or
a sponsor that adopts NCNU-5 self-audit and still receives a sponsor-side language violation finding from a regulator review — indicating NCNU-5 is insufficient as a self-audit pattern.
Both paths are open. Regulators and sponsors are invited to challenge.
AS-001 (cure lexicon smuggle) — should not occur · audit gate G2.2
AS-004 (clinical decision directive smuggle / NCNU P_1) — should not occur · audit gate G2.4
AS-008 (cross-domain conflation smuggle) — should not occur · audit gate G4.2 + W6.3 veto
Ferry target (per W6.6)
Primary: m560 GTO_Ecosystem_Control_Plane — gov_rfc to propose audit_role frontmatter as cross-project sponsor self-audit pattern.
Secondary candidate: m622 — conf_pack for regulator-adjacent conference (informational only).
Frontmatter `ferry_target: m560`.
Honest verdict (per W6.5)
已做: regulator-facing reading layer · structural-analog claim with informational framing · 3 attack-surface refs · falsifying prediction with two paths.
待办: explicit cross-mapping table to a specific regulator framework (e.g., FDA Center for Biologics Evaluation review primitives) — open work pending v0.3 (requires regulator-side input via _ops/).
漏洞: structural analog is asserted without regulator-side validation; if a regulator reviewer reads this and disagrees, the analogy is filed under _ops/BLOCKED_LOG.md and downgraded. NCNU-5 sufficiency-as-self-audit-pattern is unproven empirically — v0.3 needs ≥ 3 sponsor self-audits applying NCNU-5 to test.
反驳预案:
- *"You're claiming Roll equals FDA review."* — No. Structural-analog is read above with explicit informational framing. The point is not equivalence; the point is sponsor self-audit pattern transfer.
- *"NCNU-5 is too narrow."* — Open finding. v0.3 expansion target.
- *"This is a regulatory affairs pitch."* — No. m625 does not pitch regulatory adoption. The demo exists to help reviewers and sponsors *think* about the analogy, not to advocate it.